Online inquiry

IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10666MR)

This product GTTS-WQ10666MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10666MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4766MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ2544MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ1021MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ15145MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ4405MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ13545MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ3830MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ13249MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-05335810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW